Lupus erythematosus - Lupus Eritematosus
☆ AI Dermatology — Free Service
Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Katon minangka eritema sing rada ungu‑ungu.
Ruam kupu sing biasane katon ing rai.
relevance score : -100.0%
ReferencesNgenali lan nggolongake cutaneous lupus erythematosus (CLE) nyebabake tantangan diagnostik, amarga kudu dibedakake saka systemic lupus erythematosus sing uga melibatkan kulit. Panalitèn anyar nuduhaké faktor genetik, lingkungan, lan imunologis sing ndasari CLE. Induksi obat khusus wis dadi salah siji pemicu paling penting kanggo CLE. Perawatan kalebu terapi topikal lan sistemik, kalebu biologis sing menjanjikan (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059), kanthi khasiat sing dituduhaké ing uji klinis.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) nyakup macem‑macem masalah kulit, lan sawetara bisa uga ana hubungane karo masalah kesehatan liyane. Penyakit iki dikategorikaké dadi sawetara jinis, antara liya acute CLE (ACLE), sub‑acute CLE (SCLE), lan chronic CLE (CCLE). CCLE kalebu discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus, lan lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus minangka klompok penyakit otoimun sing bisa ngaruhi macem‑macem bagean awak. Sawetara jinis, kayata systemic lupus erythematosus (SLE), ngaruhi macem‑macem organ, dene liyane, kayata cutaneous lupus erythematosus (CLE), utamane ngaruhi kulit. Kita nggolongake macem‑macem jinis CLE adhedhasar campuran tandha klinis, pemeriksaan jaringan, lan tes getih, nanging ana akeh variasi ing antarane individu. Masalah kulit asring berkembang amarga faktor kaya cahya srengenge, ngrokok, utawa obat‑obatan tartamtu.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Penyebab Lupus Eritematosus (Lupus erythematosus) ora jelas. Ing kembar identik, yen siji kena pengaruh ana kemungkinan 24 % sing liyane uga bakal kena. Hormon seks wanita, sinar matahari, ngrokok, kekurangan vitamin D, lan infeksi tartamtu uga diyakini bisa nambah risiko.
Pangobatan bisa kalebu NSAID, kortikosteroid, imunosupresan, hydroxychloroquine, lan methotrexate. Sanajan kortikosteroid efektif, panggunaan jangka panjang bisa nyebabake efek samping.